International Journal of Molecular Medical Science, 2025, Vol.15, No.6, 253-262 http://medscipublisher.com/index.php/ijmms 262 Yepes-Cortés C., Cardenas-Moreno I., Daza-Arnedo R., Feriz-Bonelo K., Yama-Mosquera E., Ramírez-Rincón A., Castillo-Barrios G., Suarez-Rodriguez A., Carreño-Jiménez J., and Builes-Montaño C., 2025, Combining GLP-1 receptor agonists and SGLT2 inhibitors in type 2 diabetes mellitus: a scoping review and expert insights for clinical practice utilizing the nominal group technique, Diabetes Therapy, 16: 813-849. https://doi.org/10.1007/s13300-025-01722-x Zatterale F., Longo M., Naderi J., Raciti G., Desiderio A., Miele C., and Beguinot F., 2020, Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes, Frontiers in Physiology, 10: 1067. https://doi.org/10.3389/fphys.2019.01607 Zhang S., Yu B., Xu J., Jin S., Li Y., Bing H., Li J., X., Zhang X., and Zhao L., 2025, Quantitative comparison of glucagon-like peptide-1 receptor agonists on weight loss in adults: a systematic review and model-based meta-analysis, Diabetes Technology and Therapeutics, 27: 422-429. https://doi.org/10.1089/dia.2024.0533 Zhao X., Wang M., Wen Z., Lu Z., Cui L., Fu C., Xue H., Liu Y., and Zhang Y., 2021, GLP-1 receptor agonists: beyond their pancreatic effects, Frontiers in Endocrinology, 12: 721135.
RkJQdWJsaXNoZXIy MjQ4ODYzNA==